Universal leukocyte reduction: Is it appropriate medical practice or not?

Journal of Infusion Nursing

Volumn 28, Issue 4, 2005, Pages 273-281

  Angelbeck, Judy H ^a   Ortolano, Girolamo A ^a  

^a PALL CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; BLOOD TRANSFUSION; IMMUNOMODULATION; LEUKOCYTE; LEUKOCYTE REDUCED BLOOD; MEDICAL PRACTICE; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 23044489638     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200507000-00010     Document Type: Review

References (53)

1. Klein HG. Wolf in wolfs clothing: is it time to raise the bounty on the passenger leukocyte? Blood. 1992;80:1865-1868.
2. Ortolano GA, Russell RL, Angelbeck JA, Schaffer J, Wenz B. Contamination control in nursing with filtration: Part 2. Emerging rationale for bedside (final) filtration of prestorage leukocyte-reduced blood products. J Infus Nurs. 2004;27(3):157-165.
3. Wortham ST, Ortolano GA, Wenz B. A brief history of blood filtration: clot screens, microaggregate removal, and leukocyte reduction. Transfus Med Rev. 2003;17(3):216-222.
4. Blood Products Advisory Committee 60th Meeting, Volume II. Available at: http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3450t2.rtf or http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3450t2.pdf. Accessed September 18, 1998.
5. Advisory Committee on Blood Safety and Availability-Bloodsafety Resolution, January 2001. Available at: http://www.hhs.gov/bloodsafety/ resolutions/resjan01.html. Accessed January 29, 2001.
6. Advisory Committee on Blood Safety and Availability-Bloodsafety Summary, January 2001. Available at: http://www.hhs.gov/bloodsafety/summaries/sumjan01. html. Accessed February 1, 2001.
7. Circular of Information-for the use of blood and blood components. American Association of Blood Banks. Available at: http://www.aabb.org/ all_about_blood/coi/coi0702.pdf. Accessed July, 2002.
8. Brittingham TE, Chaplin H. Febrile transfusion reactions caused by sensitivity to donor leukocytes and platelets. J American Med Assn. 1957;165:819-825.
9. Patterson BJ, Freedman J, Blanchette V, et al. Effect of premedication guidelines and leukoreduction on the rate of febrile nonhaemolytic platelet transfusion reactions. Transfus Med. 2000;10(3):100-206.
10. Heddle NM. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol. 1999;6(6):420-426.
11. Enright H, Davis K, Gernsheimer T, McCullough JJ, Woodson R, Slichter SJ. Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion. 2003;43(11):1545-1552.
12. Yazer MH, Podlosky L, Clarke G, Nahirniak SM. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion. 2004;44(1):10-15.
13. Paglino JC, Pomper GJ, Fisch GS, Champion MH, Snyder EL. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion. 2004;44(1):16-24.
14. King KE, Shirey RS, Thoman SK, Bensen-Kennedy D, Tanz WS, Ness PM. Universal leukoreduction decreases the incidence of febrile non hemolytic transfusion reactions to RBCs. Transfusion. 2004;44(1):25-29.
15. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337:1861-1869.
16. Hebert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA. 2003;289(15):1941-1949.
17. Terasaki PI, Cook D. Chronic Rejection Registry. HLA antibodies and organ transplant rejection. Available at: www.ihwg.org/components/rejection.htm. Accessed June 3, 2005.
18. Bowderi RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86(9):3598-3603.
19. Roback JD. CMV and blood transfusions. Rev Med Virol. 2002;12(4):211-219.
20. Strauss RG. Leukocyte-reduction to prevent transfusion-transmitted cytomegalovirus infections. Pediatr Transplant. 1999;3(Suppl 1):19-22.
21. Lipson ST, Shepp DH, Match ME, Axelrod FB, Whitbread JA. Cytomegalovirus infectivity in whole blood following leukocyte reduction by filtration. Am J Clin Pathol. 2001;116(1):52-55.
22. Opelz G, Sengar DP, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc. 1973;5(1):253-259.
23. Opelz G, Terasaki PI. Prolongation effect of blood transfusions on kidney graft survival. Transplantation. 1976;22(4):380-383.
24. Opelz G, Vanrenterghem Y, Kirste G, et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation. 1997;63(7):964-967.
25. Taylor RW, Manganaro L, O'Brien J, Trottier SJ, Parkar N, Veremakis C. Impact of allogeneic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med. 2002;30(10):2249-2254.
26. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288(12):1525-1526.
27. Claridge JA, Sawyer RG, Schulman AM, McLemore EC, Young JS. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am Surg. 2002;68(7):566-572.
28. Koval KJ, Rosenberg AD, Zuckerman JD, et al. Does blood transfusion increase the risk of infection after hip fracture? J Orthop Trauma. 1997;11(4):260-265.
29. Chelemer SB, Prato BS, Cox PM Jr, O'Connor GT, Morton JR. Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery. Ann Thorac Surg. 2002;73(1):138-142.
30. Leal-Noval SR, Rincon-Ferrari MD, Garcia-Curiel A, et al. Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. Chest. 2001;119(5):1461-1468.
31. Offner PJ, Moore EE, Biffl WL, Johnson JL, Silliman CC. Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg. 2002;137(6):711-716.
32. Gianotti L, Pyles T, Alexander JW, Fukushima R, Babcock GF. Identification of the blood component responsible for increased susceptibility to gut-derived infection. Transfusion. 1993;33(6):458-465.
33. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol. 1994;12(9):1859-1867.
34. Blumberg N, Heal JM. Blood transfusion immunomodulation: the silent epidemic. Arch Pathol Lab Med. 1998;122(2):117-119.
35. Sweeney JD. Leukoreduction of the blood supply in Rhode Island. Med Health. 1998;81:386-391.
36. Sherman LA. Universal leukoreduction: state of the art and the nature of decision making. Arch Pathol Lab Med. 2002;126 (2):220-222.
37. Farrugia A. Universal leucocyte reduction of blood components: a need for evidence-based decision making. Dev Biol (Basel). 2002;108:112-120.
38. Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg. 1992;79:513-516.
39. Heiss MM, Mempel W, Jausch K-W, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet. 1993;342:1328-1333.
40. Busch ORC, Hop WCJ, van Papendrechy MAWH, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med. 1993;328:1372-1376.
41. Houbiers JGA, Brand A, van de Watering LMG, et al. Randomized controlled trial comparing transfusion of leukocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet. 1994;344:573-578.
42. Jensen LS, Kissmeyer-Nielsen P, Wolff B, et al. Randomized comparison of leukocyte-depleted versus buffy-coat poor blood transfusion and complications after colorectal surgery. Lancet. 1996;348:841-845.
43. van de Watering LMG, Hermans J, Horbiers JGA, et al. Beneficial effect of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation. 1998;97:562-568.
44. Vamvakis EC. Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: the effects of the type of transfused red blood cell product and surgical setting. Trans Med Rev. 2002;16:304-314.
45. Ortolano GA, Russell R, Capetandes A, Wenz B. Transfusion-associated immunosuppression: heuristic model or clinical concern. Mod Aspects Immunobiol. 2002;2(4):159-165.
46. Wallis JP, Champman CE, Orr KE, et al. Effects of white cell depletion of red cells on postoperative infection rates in cardiac surgery (supplement and abstract). Transfus Med. 1999;9:43S.
47. Titlestad IL, Ebbesen LS, Ainsworth AP, et al. Leukocyte depletion of blood components does not significantly reduce the risk of infectious complications: results of a double-blinded randomized study. Int J Colorectal Dis. 2001;16:147-153.
48. Bilgin YM, van de Watering LMG, Lorinser JE, et al. The effects of prestorage leukocyte depletion of erythrocyte concentrates in cardiac surgery: a double-blind randomized clinical trial (supplement and abstract). Blood. 2001;98(11):828a-829a.
49. Vamvakis EC, Dzik W, Blajchman MA. Deleterious effects of transfusion-associated immunomodulation: appraisal of the evidence and recommendations for prevention. In: Vamvakas EC, Blajchman MA eds. Immunomodulatory Effects of Blood Transfusion. Bethesda, Md: AABB Press; 1999:253-285.
50. Hebert PC, Fergusson D, Blahchman MA, et al. Clinical outcomes following institution of the Canadian universal leukocyte reduction program for red blood cell transfusions. JAMA. 2003;15:1941-1949.
51. Llewelyn CA, Taylor RS, Todd AAM, et al. The effect of universal leukoreduction on postoperative infections and length of hospital stay in elective orthopedic and cardiac surgery. Transfusion. 2004;44:489-500.
52. Blajchman MA. Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse? Transfusion. 1999;39:665-670.
53. Hill AB. The environment and disease: association or causation? (President's address). Proc Roy Soc Med. 1965;58:295-300.